EU/3/15/1522

About

On 28 July 2015, orphan designation (EU/3/15/1522) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for humanised IgG4 monoclonal antibody against extracellular tau for the treatment of progressive supranuclear palsy.

The sponsorship was transferred to Biogen Idec Limited, United Kingdom, in August 2017.

The sponsorship was transferred to Biogen Netherlands B.V. Netherlands, in April 2019.

Key facts

Active substance
Humanised IgG4 monoclonal antibody against extracellular tau
Disease / condition
Treatment of progressive supranuclear palsy
Date of first decision
28/07/2015
Outcome
Positive
EU designation number
EU/3/15/1522

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Biogen Netherlands B.V.
Prins Mauritslaan 13-19
Badhoevedorp
Noord-Holland
1171 LP
Netherlands
Tel. + 31 20 542 2140
E-mail: ukreceptiondesk@biogen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating